Neuroendocrine differentiation in prostate cancer: a sheep in wolf's clothing? (original) (raw)

• Amato K et al. (1992) Chemotherapy for small cell carcinoma of prostatic origin. J Urol 147: 935–937
  Article CAS Google Scholar
• Tetu B et al. (1987) Small cell carcinoma of the prostate: part I-A clinicopathologic study of 20 cases. Cancer 59: 1803–1809
  Article CAS Google Scholar
• Oesterling JE et al. (1992) Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistochemical study of 27 patients. J Urol 147: 804–807
  Article CAS Google Scholar
• Howe MC et al. (2005) Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy. Histopathology 46: 195–201
  Article CAS Google Scholar
• Azzopardi JG and Evans DJ (1971) Argentaffin cells in prostatic carcinoma: differentiation from lipofuscin and melanin in prostatic epithelium. J Pathol 104: 247–251
  Article CAS Google Scholar
• Pearse AG and Takor T (1979) Embryology of the diffuse neuroendocrine and its relationship to the common peptides. Fed Proc 38: 2288–2294
  CAS PubMed Google Scholar
• Schron DS et al. (1984) The histogenesis of small cell carcinoma of the prostate: an immunohistochemical study. Cancer 53: 2478–2480
  Article CAS Google Scholar
• Bostwick DG et al. (1994) Neuroendocrine differentiation in prostate intrapeithelial neoplasia and adenocarcinoma. Am J Surg Pathol 18: 1240–1246
  Article CAS Google Scholar
• Di Sant'Agnese PA (2001) Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. Ann Oncol 12 (Suppl): S135–S140
  Article Google Scholar
• Di Sant'Agnese PA (2000) Divergent neuroendocrine differentiation in prostatic carcinoma. Sem Diagn Pathol 17: 149–161
  CAS Google Scholar
• Muzzonigro G and Galosi AB (2002) Biological selection criteria for radical prostatectomy. Ann NY Acad Sci 963: 204–212
  Article Google Scholar
• Helpap B et al. (1999) Undifferentiated carcinoma of the prostate with small cell features: immunohistochemical subtyping and reflections on histogenesis. Virchows Arch 434: 385–391
  Article CAS Google Scholar
• Helpap B et al. (1999) Neuroendocrine differentiation in prostate carcinomas: histogenesis, biology, clinical relevance, and future therapeutic perspectives. Urol Int 62: 133–138
  Article CAS Google Scholar
• Bonkhoff H and Remberger K (1996) Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 28: 98–106
  Article CAS Google Scholar
• Bonkhoff H (1998) Neuroendocrine cells in benign and malignant prostate tissue morphogenesis, proliferation, and androgen receptor status. Prostate 8 (Suppl): S18–S22
  Article Google Scholar
• Wang Q et al. (2004) Inhibitory effect of IL-6–induced neuroendocrine cells on prostate cancer cell proliferation. Prostate 61: 253–259
  Article CAS Google Scholar
• Algaba F et al. (1995) Neuroendocrine cells in peripheral prostatic zone: age, prostatic intraepithelial neoplasia and latent cancer-related changes. Eur Urol 27: 329–333
  Article CAS Google Scholar
• Rubinstein JH et al. (1997) Small cell anaplastic carcinoma of the prostate: seven new cases, review of the literature, and discussion of a therapeutic strategy. Am J Clin Oncol 20: 376–380
  Article Google Scholar
• Vashchenko N and Abrahamsson PA (2005) Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 47: 147–155
  Article CAS Google Scholar
• Berruti A et al. (2005) Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone refractory disease. Endocr Relat Cancer 12: 109–117
  Article CAS Google Scholar
• Amorino GP and Parsons SJ (2004) Neuroendocrine cells in prostate cancer. Crit Rev Eukaryot Gene Expr 14: 287–300
  Article CAS Google Scholar
• Bostwick DG et al. (2002) Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival. J Urol 168: 1204–1211
  Article Google Scholar
• Daneshmand S et al. (2005) Ethnic differences in neuroendocrine cell expression in normal prostatic tissue. Urology 65: 1008–1012
  Article Google Scholar
• Tokunaga M et al. (2005) Association of neuroendocrine differentiation with neoadjuvant hormone therapy effects in prostate cancer. Oncol Rep 13: 1081–1087
  PubMed Google Scholar
• Iwamura M et al. (1998) Receptors for BPH growth factors are located in some neuroendocrine cells. Prostate 8 (Suppl): S14–S17
  Article Google Scholar
• Wu JT et al. (1998) Serum chromogranin A: early detection of hormonal resistance in prostate cancer patients. J Clin Lab Anal 12: 20–25
  Article CAS Google Scholar
• Cussenot O et al. (1996) Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol 155: 1340–1343
  Article CAS Google Scholar
• Syversen U et al. (2004) Clinical significance of elevated serum chromogranin A levels. Scand J Gastroenterol 39: 969–973
  Article CAS Google Scholar
• Sciarra A et al. (2003) Neuroendocrine differentiation in human prostatic tissue: is it detectable and treatable. BJU Int 91: 438–445
  Article CAS Google Scholar
• Angelsen A et al. (1997) Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate. Prostate 31: 110–117
  Article CAS Google Scholar
• Birtle AJ and Freeman A (2003) Neuroendocrine differentiation in prostate cancer: is it detectable and treatable? Br J Urol 92: 490–492
  Article CAS Google Scholar
• Cox ME et al. (1999) Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cancer Res 59: 3821–3830
  CAS PubMed Google Scholar
• Di Sant'Agnese AP (1995) Neuroendocrine differentiation in prostatic carcinoma. Cancer 75 (Suppl): S1850–S1859
  Article Google Scholar
• Wynick D and Bloom SR (1991) Clinical review 23: the use of long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors. J Clin Endocrinol Metab 73: 1–3
  Article CAS Google Scholar
• Kadar T et al. (1988) Receptors of prolactin, somatostatin, and luteinizing hormone-releasing in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing and somatostatin. Proc Natl Acad Sci USA 85: 890–894
  Article CAS Google Scholar
• Venkatesh PJ et al. (2004) Metastatic pure small-cell carcinoma of prostate. Am J Med Sci 328: 286–289
  Article Google Scholar
• Papandreou CB et al. (2002) Results of phase II study with doxorubicin, etoposide and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 20: 3072–3080
  Article CAS Google Scholar
• Kelly WK et al. (1993) Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11: 607–615
  Article CAS Google Scholar
• Bonkhoff H and Fixemer T (2004) Neuroendocrine differentiation in prostate cancer. An unrecognized and therapy-resistant phenotype [German]. Urologe A 43: 836–842
  Article CAS Google Scholar
• Moore SR et al. (1992) Small cell carcinoma of the prostate: effectiveness of hormonal versus chemotherapy. Urology 39: 411–416
  Article CAS Google Scholar
• Sundin A et al. (2004) PET in the diagnosis of neuroendocrine tumors. Ann NY Acad Sci 1014: 246–257
  Article CAS Google Scholar
• Schwartz LH et al. (1998) Small cell and anaplastic prostate cancer: correlation between CT findings and prostate-specific antigen level. Radiology 208: 735–738
  Article CAS Google Scholar
• Matsumori N et al. (2004) An allograft model of androgen independent prostatic neuroendocrine carcinoma derived from a large probasin promoter-T antigen transgenic mouse line. J Urol 171: 439–442
  Article Google Scholar
• True L (2004) Why we must better understand neuroendocrine differentiation in prostate cancer. J Urol 171: 443–444
  Article Google Scholar